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ABSTRACT In this report, we determined that induction
of the DR a-chain gene by recombinant human interferon-y
(IFN-y) in a human glioblastoma multiform cell line is tran-
scriptionally regulated and showed that protein synthesis is not
necessary for this to occur. The regions of the DR a-chain gene
that are responsible for basal and recombinant IFN-y-induced
gene transcription have been determined by gene transfer of a
series of 5' deletion mutants in which the upstream region of the
DR a chain was linked to a reporter gene, chloramphenicol
acetyltransferase. Chloramphenicol acetyltransferase transcript
and protein levels were determined by S1 nuclease protection
and chloramphenicol acetyltransferase enzyme assays, respec-
tively. By using these deletion mutants, we were able to draw the
following conclusions. (i) One hundred and nine base pairs of
upstream sequence contains the basicDR a-chain gene promoter
and represents the minimal amount of sequence necessary for
basal gene expression. (ii) An additional 9 base pairs ofupstream
sequence can mediate recombinant IFN-y induction. (iii) Max-
imal recombinant IFN-y induction requires at most an addi-
tional 23 base pairs of upstream sequence. (iv) The sequence
between positions -267 and -141 does not appear to contain
any additional positive or negative regulatory elements. These
results suggest that the region between positions -141 and
-109 contains a critical IFN-Y-responsive element. Substitution
mutagenesis was performed to confirm this suggestion.
Class II major histocompatibility complex (MHC) antigens
are crucial to the overall function of the immune system by
virtue of their role in antigen presentation and lymphocyte
interaction (1, 2). The quality of an immune response is
determined in part by the timing and extent of class II antigen
expression; therefore, the molecular regulation of these
genes is of primary importance.
The class II MHC genes are regulated in a complex fashion
and provide one ofthe most interesting systems to study gene
regulation. Expression patterns of class II antigens are
extremely diverse and tightly regulated (3-8). It is assumed,
therefore, that complex mechanisms must be in place that
control the tissue-specific, differentiation-dependent, and
inducible expression of class II genes.
Several laboratories including our own have begun to
examine these controlling mechanisms and to identify cis-
acting DNA sequences responsible for class II MHC gene
regulation (9-16). The present report centers on the detailed
delineation of interferon-y (IFN-y)-responsive regions in the
DR a-chain (DRa) gene by using a human glioblastoma
multiform line as a model system. We have been particularly
interested in the basal and inducible expression of these
antigens on glioblastomas because class II antigen expression
in the brain has been linked to the initiation and propagation
of autoimmune-like diseases of the central nervous system.
In this paper, we have shown that DRa induction by IFN-y
is transcriptionally regulated. In addition, we have mapped
the IFN-y-responsive regions of the gene encoding DRa to
two short DNA segments, each containing a single copy of a
heptamer sequence. The significance of this finding to class
II MHC gene expression and to the mechanism of IFN-y-
induced gene expression will be discussed.
MATERIALS AND METHODS
Cell Lines and Reagents. The U-373-MG human glio-
blastoma multiform cell line (17) was obtained from D. Bigner
(Duke University, Durham, NC). Recombinant human
IFN-y (rIFN-'y) was generously provided by Biogen (Bos-
ton). S1 nuclease was purchased from Bethesda Research
Laboratories. RNase-free DNase was purchased from Phar-
macia.
Plasmids. Plasmids 5'A-1028 and 5'A-267 contain 1028 and
267 base pairs (bp) of the upstream sequence for the gene
encoding DRa and are identical to pDR1000 and pDR300,
respectively, as described (9). Plasmids in the nested deletion
series 5'1A-177 to 5'A&-53 were derived from pDRA1000 as
described (10). All of the aforementioned plasmids will be
designated pDRa-CAT deletion mutants.
An additional deletion mutant, 5'A-56(xbaI), was prepared
in which an Xba I linker was placed immediately upstream of
the sequence encoding DRa. This plasmid was used to
construct a substitution mutant in the putative IFN-y-
responsive region. After linearization with Xba I and blunt-
ending with the Klenow fragment ofDNA polymerase I, two
81-bp oligonucleotides were cloned into the Xba I site of
5'A-56(xbal). The first oligonucleotide corresponds to the




struct was designated pwt-IRE-yII. The second oligonucle-
otide corresponds to the 5' sequence of the gene encoding
DRa from position -141 to position -61; however, the
sequence from position -141 to position -109 was randomly
mutated to 5'-AGGTGTGAAGTTCAAAGGGTACCTC-
CAAAGGCC-3'. This construct has been designated pmut-
IRE-yII.
The negative control plasmid pD164-2 contains the chlor-
amphenicol acetyltransferase (CAT) gene and was derived as
described (9). Plasmid pSV2CAT is identical to that de-
Abbreviations: CAT, chloramphenicol acetyltransferase; IFN-y,
interferon-,y; rIFN-y, recombinant human IFN--y; IRE-yII, class II
IFN-y-responsive element; MHC, major histocompatibility com-
plex; DRa, a chain of DR.
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transfection as described (24) and was used in RNA protec-




FIG. 1. IFN-y induction of DRa-specific RNA in the glio-
blastoma U-373-MG is transcriptionally regulated and does not
require de novo protein synthesis, as measured by a nuclear run-on
analysis. [32P]UTP-labeled nuclear transcripts were prepared from
untreated, rIFN-y- (500 units/ml), rIFN-y- plus cycloheximide- (CH,
10 tg/ml) treated, or cycloheximide-treated U-373-MG cells. Equiv-
alent numbers of nuclei were used to prepare [32P]UTP-labeled
nascent transcripts, and the total cpm were not further equilibrated.
These labeled transcripts were then used to probe plasmid DNA
specific for t-actin, DRa, and pBR328 nucleotide sequences.
scribed by Gorman et al. (18). The plasmid used to produce
an antisense RNA probe for S1 nuclease analysis is pGEM-
DRa-CAT. It was constructed by excising an Xba I-EcoRI
fragment from 5'A-1028 that contains 295 bp of the upstream
sequence of the gene encoding DRa and 266 bp of the CAT
structural gene. This fragment was cloned into the Xba I and
EcoRI polylinker sites of pGEM3-Blue (Promega, Madison,
WI).
Nuclear Run-On Transcription Assay. Nuclei were pre-
pared after 24 hr from untreated, rIFN-y-treated (500
units/ml), rIFN-y- and cycloheximide-treated (10 mg/ml), or
cycloheximide-treated U-373-MG cells. From these nuclei,
nascent transcripts were radiolabeled, isolated, and used as
-hybridization probes against plasmid DNA immobilized on
nitrocellulose as described (19, 20). Plasmid p34-RI-3 (21),
provided by Sherman Weissman (Yale University), was used
to identify DRa-specific transcripts. Plasmid pHF1 (22)
coding for human y-actin served as a standardizing control
and plasmid pBR328 was used to control for nonspecific
binding.
Transfection. Transfection of the glioblastoma cell line was
performed by the calcium phosphate method as described by
Graham and van der Eb (23) or through electroporation with
a Bio-Rad gene pulser under the following conditions. Briefly
3 x 10' subconfluent U-373-MG cells in 300 ,ul of complete
medium were pulsed at 200 V at a capacitance setting of 960
,uF. Exact specifications of rIFN-y treatment have been
described (9).
CAT Assay. CAT activity produced in transfected cells was
assayed according to the method of Gorman et al. (18).
Acetylated products were visualized by autoradiography of
TLC plates. Quantitative measurements were obtained by
cutting out both the acetylated and unacetylated spots and
measuring radioactivity separately in a scintillation counter;
from these data percent acetylation was calculated.
RNA Isolation and S1 Nuclease Protection Analysis. RNA










IFN-y Induction of DRa-Specific RNA in the Glioblastoma
U-373-MG Is Transcriptionally Regulated and Does Not Re-
quire de Novo Protein Synthesis. To determine if IFN-y
induction of the human class II gene DRa in U-373-MG cells
is transcriptionally regulated and to determine if protein
synthesis is necessary for this induction, we performed
nuclear run-on experiments. The results from a repre-
sentative experiment are shown in Fig. 1. A definite increase
in DRa-specific transcripts (row 3) was observed from
IFN-y- and IFN-y-plus cycloheximide-treated cells. Densi-
tometric measurements of DRa-specific transcripts in the
untreated and cycloheximide-treated cells (columns 1 and 4)
compared to their respective IFN-y-treated counterparts
show that the induction of nascent DRa transcripts is >4-fold
in the absence of cycloheximide and >7-fold in the presence
of cycloheximide. It has been demonstrated that steady-state
DRa mRNA is induced 4- to 8-fold by IFN-y in this cell line
(26). Therefore in the present system, the majority, if not all,
of the regulation of IFN-y induction of DRa is due to an
increased rate of transcription. In addition we have shown
that this increase does not require protein synthesis.
Description of a Nested Series of 5' pDRa-CAT Deletion
Mutants. To analyze regions of the DRa gene -that are
important in the IFN-y-induced gene transcription, a series of
deletion mutants of the 5' regulatory region of the gene
encoding DRa was prepared and characterized as described
(10) and are illustrated in Fig. 2. These DRa sequences were
all cloned upstream ofthe indicator gene CAT in pD164-2 (9).
The nine deletion mutants illustrated in Fig. 2 range from
positions -1028 to -53 of the DRa gene and all contain a
putative CAAT box, a TATA box, and the transcriptional
start site. Constructs 5'A-1028 through 5'A-109 all contain the
class II boxes (X + Y), which are two conserved upstream
sequences present in all class II MHC genes (27). 5'A-91
contains only the 3' class II box, and 5'A-53 contains neither.
DRa Upstream Sequences Important in Basal and rIFN-y-
Induced Gene Expression. The deletion mutants illustrated in
Fig. 2 were used in DNA transfection experiments to analyze
the ability of various upstream regions of DRa to mediate
basal and rIFN-y-induced expression of the CAT gene. CAT
activity was determined by measuring the ability of trans-
fected cell extracts to acetylate the substrate [14C]chlor-
amphenicol as described (9). Table 1 represents a summary
ofmore than 13 experiments in which percent acetylation was
determined. Each value is based on the average of various
numbers of transfection experiments. Inherent variability of
transfection and CAT assays necessitated the performance of
a large number of experiments with each construct and the
performance of statistical analysis. The fold induction was
calculated by dividing the average percent acetylation values
ofrIFN-ytreated cultures by the average values of untreated
cultures. The significance of the induced values versus the
uninduced values was determined by a two-sided t test and
CAT
Iv)
In'- In-FIG. 2. A map of 5' pDRa-CAT deletion
I I I mutants used in transfection experiments.
Nucleotide numbers in the pictured constructs
Ip. (.) are numbered relative to the DRa cap site.
The DRa sequences were all cloned upstream of
theCAT structural gene Ea. Boxes labeledXand
{}°0 I Iz~z%44z%%z/4%zS Y designate two conserved upstream sequences
X Y CAAT TATA found in all class II genes.
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Table 1. Basal expression and IFN-y induction potential of 5'
DRa sequences
pDRa-CAT Exp., IFN-y % Fold
construct n treatment acetylation induction P
5'A&-267 13 - 0.7
+ 9.2
5'A-177 7 - 0.6
+ 5.6
5'A-155 2 - 0.4
+ 2.9
5'A-141 5 - 0.9
+ 7.6
5'A-118 E 3 - 0.9
+ 2.1
5'A-109 8 - 0.7
+ 0.7
5'A-91 2 - 0.1
+ 0.1
5'A-53 4 - 0.2
+ 0.2











For P<, mean acetylation values from both treated and untreated
samples were compared in a two-sided t test. ND, not done; NS, not
significant; -, no IFN-y treatment; +, IFN-y treatment.
these P values are also shown. The composite of these data
illustrates the following two points. (i) The basal DRa
promoter is intact and contained in construct 5'A-109 and in
all other constructs with at least this much of 5' DRa
sequence. Further S' deletions (constructs 5'A-91 and 5'A-53)
cause a loss of basal expression to the baseline value of the
negative control plasmid pD164-2. The higher level of basal
expression seen with construct 5'A-109 versus 5'A-53 or
pD164-2 was very consistent. (ii) Unlike basal promotor
activity, rIFN-y responsivity is not contained in 5'A-109;
however, an additional 9 bp of upstream sequence (construct
5'A-118) results in some rIFN-y induction, although the P
value only shows significance at the 0.1 level. For maximal
rIFN-y induction, however, sequences between bp -118 and
-141 are necessary (P values ranging from 0.001 to 0.01).
Sequences further upstream of bp -141 (constructs 5'A-
155, 5'A-177, and 5'A-267) do not appear to contain additional
rIFN-y-responsive elements as shown by additional statisti-
cal analysis (Table 2). These data indicate that the fold-
induction values obtained with constructs 5'A-177, 5'A-155,
and 5'A-141 are not significantly different from construct
5'A-267, whereas the fold-induction value for construct
5'A-118 is only different from 5'A-267 at a significance value
of 0.1.
Substitution Mutation of the MHC Class II IFN-y-
Responsive Element (IRE-yH) Results in Loss of IFN-y Induc-
ibility. To better define the functional role ofDNA sequences
between bp -141 and -109 in IFN-y induction, a substitu-
tion mutant (pmut-IRE-yII) was used in transfection exper-
iments. A control construct with wild-type sequences (pwt-
Table 2. Lack of additional IFN-y-responsive elements upstream
of bp -141 in DRa
pDRa-CAT Exp., Induction of test construct/
construct n induction of 5'A-267, fold/fold P
5'A-267 9 1
5'A-177 5 1 NS
5'A-155 2 0.8 NS
5'A-141 5 0.9 NS
5'A-118 2 0.19 <0.1
For P, normalized induction ratios were compared in a two-sided
t test.
Table 3. Loss of rIFN-y inducibility by substitution mutations in
the IRE-,yII
pDRa-CAT rIF(N-y







For % acetylation, each value is an average of two experiments.
IRE-yII) was also examined. In addition the original deletion
mutant 5'A-56(xbal), into which either mutated or wild-type
sequences were cloned, was included as a baseline control.
Results from transfection experiments with these constructs
are shown in Table 3. The results demonstrate that mutating
the DRa region from bp -141 to bp -109 (pmut-IRE-yII)
abolishes IFN-y-inducible CAT expression. However, when
the wild-type control plasmid pwt-IRE-yII was used, IFN-y
inducibility was preserved. This definitively demonstrates
the importance of this region in IFN-y-regulated DRa gene
expression. Hence we have designated this region ofthe DRa
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FIG. 3. S1 nuclease protection ofDRa-CAT RNA. A S1 nuclease
protection analysis of total cellularRNA isolated from the U-373-MG
glioblastoma transfected with the plasmids SV2-CAT, 5'A-267 (A),
and 5'A-141 (B) is shown. Cells transfected with 5'A-267 and 5'A-141
were either untreated (-) or treated (+) with rIFN--y (500 upits/ml).
Total cellular RNAs isolated from pSV2-CAT transfected cells (35
,ug), 5'A-267 and 5'A-141 transfected cells (70,g), untransfected cells
(70 pg), or control tRNA (70 Mg) were hybridized with a "2P-labeled
antisense transcript initiated from the T7 promoter of pGEM-DRa-
CAT by the procedure of Melton et al. (29). This antisense probe
contained 266 nucleotides of the CAT structural gene, 295 nucleo-
tides ofDRa sequence, and 23 bp ofpGEM3-Blue sequence. Hybrids
were then digested with 5 units of S1 nuclease and electrophoresed
on a denaturing 6% polyacrylamide gel. In the marker lane M,
'2P-labeled Hpa II-digested pBR322 was electrophoresed for size
determination. Predicted sizes of protected fragments are shown (C).
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To determine whether the 5' DRa region from bp -141 to
bp -109 could cause IFN-'y induction by itself, we cloned an
oligonucleotide corresponding to this region into a pDRa-
CAT vector containing only the DRa TATA box and a
putative CAAT box but lacking the class II box sequences.
This oligonucleotide was also cloned into the vector
PA1OCAT in which CAT is promoted only by the simian virus
40 promoter region (28). Neither of these constructs was able
to promote IFN-y-induced expression of CAT (data not
shown). This suggests that the IRE-yII defined here needs to
be in the context of other class II sequences (potentially the
class II boxes) to exert its effect.
Si Nuclease Protection Analysis of RNA Obtained from
pDRa-CAT Deletion Mutant Transfections. To determine the
transcriptional start site and the levels of CAT-specific RNA
in U-373-MG cells transfected with pDRa-CAT, RNA was
isolated and subjected to S1 protection analysis. Fig. 3A
represents the results from such an experiment where RNA
samples obtained from cells transfected with a positive
control plasmid, pSV2-CAT, and with 5'A-267 untreated or
treated with rIFN-y were analyzed. Fig. 3B shows the results
for cells transfected with 5'A-141 that were untreated or that
were treated with rIFN-y. The experiment in Fig. 3A was
performed with RNA from calcium phosphate transfected
cells, Whereas the experiment in Fig. 3B was performed with
RNA from electroporated cells.
The results illustrate that RNA from cells transfected with
pSV2CAT and cells transfected with either 5'A-267 or 5'A-
141 that have been treated with rIFN-y yielded protected
fragments of the predicted sizes (see Fig. 3C and ref. 30).
RNA from uninduced cells that were calcium phosphate
transfected with 5'A-267 showed little protection. This is in
accord with the extremely low levels of CAT protein pro-
duced by these cells. In contrast, RNA from cells that had
been electroporated with 5'A-141 in the absence of IFN-y
yielded a significant signal at both the protein level (CAT
assay not shown) and here at the RNA level (Fig. 3B),
probably because of enhanced transfection efficiency. De-
spite using RNA from cells transfected by different proce-
dures, CAT transcripts from the correct initiation site ofDRa
were utilized in both cases as shown by the presence of a
293-bp protected fragment, and the level of accurately initi-
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including cells that were not transfected with plasmids or
tRNA, did not yield any protected fragment.
DISCUSSION
The mechanism(s) by which IFN--y enhances MHC class II
antigen expression is not well understood, and the literature
on this subject is sometimes confusing. The question as to
whether or not the rIFN-y-induced changes in class II
expression are transcriptional, posttranscriptional, or trans-
lational has been raised for some time. In the present paper
we have determined that, in a glioblastoma multiform cell
line, the majority if not all of the IFN-y induction of DRa is
due to an increased rate of transcription that does not require
de novo protein synthesis. This is in accord with a report
where IFN--y induction of class II gene expression in the
mouse WEHI-3 cell line is shown to be transcriptionally
induced (31). However, this report did not determine if the
entire IFN-y-induced response could be accounted for by
increased transcription. Rosa and Fellous (30) provided
evidence that the majority ofthe IFN-y-induced DRa expres-
sion in both a melamona cell line and a skin fibroblast cell line
was posttranscriptional in nature. This raises the possibility
that IFN-y-induced class II gene expression may occur by
different mechanisms.
This study also finely mapped the IFN-y-responsive region
of DRa in the glioblastoma cells. As summarized in Fig. 4,
sequences upstream of the class II boxes are required for
IFN--y induction. Some induction is observed when an
additional 9 bp of upstream sequence are included. Interest-
ingly, the border ofbox X, as defined by Kelly and Trowsdale
(32), includes these additional 9 bp. Maximal IFN-y induc-
tion, however, requires another 23 bp of upstream sequence
(construct 5'A-141). Substitution mutagenesis, which repre-
sents a superior approach to deletion mutagenesis, confirms
the importance of a region from bp -141 to bp -109. Future
site-specific mutational analyses will elucidate the precise
nature of the IRE-,yII consensus sequence.
In the DQ 3 chain gene, a sequence between bp -159 and
bp -128 has been implicated in IFN-y induction (14). This
region and the maximal IFN-y-responsive region identified
for DRa (bp -141 to bp -119) are -50% identical. A con-
served septamer defined by Servenius et al. (33) is found in
both of these regions and in most other class II genes. The
CAT
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FIG. 4. Basal expression and IFN-y induction potential of pDRa-CAT constructs. See Table 1 for more information.
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FIG. 5. Conserved septamer sequences in class II upstream
sequences. A consensus septamer as defined by Servenius et al. (33)
is shown in the context of a number of class II MHC genes. The
regions shown here containing the conserved septamer are all
immediately upstream of the class II X box. Upstream sequences of
the genes shown here were obtained from the following references:
DRa (21), Ed (34), Ed and Al (33), and DQ8 (14).
consensus sequence of this septamer in the context of a
number of class II genes is shown in Fig. 5. Within DRa, a
septamer containing 6 of the 7 nucleotides is present between
bp -131 and -125, where maximal rIFN-y responsivity is
mapped. Interestingly, another 6/7 septamer is found in the
region of DRa (from bp -117 to bp -111), where minimal
rIFN-y responsivity was mapped. Other class II genes such
as the murine Ed and Ed also have a second copy of this
sequence in their 5' region. In contrast, the homologous
region of the gene encoding the DQ 8 chain or a number of
other class II genes-such as the P chain genes for DP, DO,
and mouse Ab-only has one copy of this septamer. Whether
these sequence differences reflect functional differences in
rIFN-y induction potential remains to be determined.
The present fine analysis of the upstream regions of the
DRa gene has identified a class II IFN-y-responsive element.
This element is clearly different from the IFN-a,,3 element
described by Friedman and Stark (35). Interestingly, in MHC
class I genes, the IFN-'y- and IFN-a,,B-responsive elements
overlap significantly (36-40). The data presented here dem-
onstrate to the best of our knowledge that this is clearly not
the case in MHC class II genes that possess an IFN-y-
responsive element that is distinct from any IFN-a,4 or -y
consensus sequences previously described.
Interestingly, we had identified (9) a conserved nonamer
present in the upstream region of the gene encoding DRa
(from bp -265 to bp -257) and of other rIFN-y-inducible
genes, including class I and II MHC genes and the 132-
microglobulin gene. The present detailed analysis of this 5'
region of DRa was unable to ascribe any functional signifi-
cance to this sequence (see Table 1 and Fig. 4, construct
A-267 vs. A-177). This supports the above results, other work
(36), and our earlier proposal (9) that the IFN-y induction of
class I and II genes may occur by different pathways.
The data presented here in combination with other reports
have provided strong evidence that class II genes contain a
number of regulatory regions both upstream to, and within,
the gene (9-16). These regulatory elements in various cellular
environments seem to account for the differential expression
of class II genes. The mechanisms by which certain regula-
tory elements take precedence over others in different cell
types await further elucidation.
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